ArticleJournal of translational medicine2026
P4HA1⁺ collagen-modifying fibroblasts are associated with pro-tumor niches and therapeutic vulnerabilities in colorectal cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCancer-associated fibroblasts (CAFs) are a major stromal component of the tumor microenvironment (TME) and actively participate in tumor progression. Although CAF heterogeneity in colorectal cancer (CRC) is increasingly recognized, how individual CAF subpopulations simultaneously coordinate extracellular matrix (ECM) remodeling, angiogenesis, and immune suppression within spatially organized niches remains poorly understood.
methodsCAF heterogeneity was systematically analyzed by integrating single-cell RNA sequencing, spatial transcriptomics, and bulk transcriptomic data. By combining cell clustering, pseudotime analysis, transcriptional regulatory network inference, spatial deconvolution, and ligand-receptor interaction analysis, we revealed the spatial distribution and cellular communication characteristics of CAF subpopulations. At the same time, machine learning-based prognostic models and transcriptional perturbation analysis were used to evaluate the clinical significance and potential therapeutic value of CAF-related transcriptional programs.
resultsWe identified a prolyl 4-hydroxylase subunit alpha 1 (P4HA1)-positive collagen-modifying CAF subpopulation (P4HA1⁺ CAFs) that was enriched in tumor tissue and exhibited collagen remodeling characteristics. This subpopulation preferentially localized at the tumor-stroma interface, co-localizing with pro-angiogenic endothelial cells, immunosuppressive macrophages, and malignant epithelial cells to form a spatially organized niche with concurrent ECM remodeling, angiogenesis, and immune suppression. P4HA1⁺ CAFs were predicted to engage distinct ligand-receptor axes, including WNT5A-MCAM with endothelial cells, MDK-LRP1 with macrophages, and MDK-NCL with malignant epithelial cells. The MDK-NCL axis was associated with increased RANBP1 expression and enhanced tumor cell proliferation and invasion. Machine learning analysis further identified P4HA1, TIMP1, ARL4C, and SFRP4 as stable core genes associated with poor prognosis. Drug perturbation analysis showed that 2-methoxyestradiol and its combination with the histone deacetylase (HDAC) inhibitor JNJ-26,481,585 may partially reverse the malignant transcriptional program of P4HA1⁺ CAFs.
conclusionsThis study characterizes a P4HA1⁺ collagen-modifying CAF subpopulation that resides within a spatially organized multicellular niche and engages distinct signaling axes to simultaneously promote angiogenesis, immune suppression, and tumor cell proliferation in CRC, highlighting its prognostic and potential therapeutic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.